17-Year-Old Girl at 13 Weeks Gestation Presents With Vaginal Bleeding &amp; Cramping

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Data from the DREAMM-7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Ariana Pelosci

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.

Jorge Nieva, MD

July 14th 2025

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Roman Fabbricatore

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Tim Cortese

Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

Related Content

Russ Conroy

July 26th 2025

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Data from the DREAMM-7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Ariana Pelosci

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.

Jorge Nieva, MD

July 14th 2025

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Roman Fabbricatore

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Tim Cortese